BiotechTube
SNIPR BIOME

SNIPR BIOME

Copenhagen, Denmark· Est.
sniprbiome.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $60M

Overview

SNIPR Biome is a private, clinical-stage biotech developing a novel platform of CRISPR-powered antimicrobials to address the global antimicrobial resistance (AMR) crisis. The company's technology combines bacteriophages or engineered probiotics with CRISPR-Cas systems to selectively kill antibiotic-resistant bacteria while sparing the beneficial microbiome. With a pipeline of five programs, including a candidate in Phase 2, and backing from major foundations and investors, SNIPR is advancing a new class of precision medicines from its Copenhagen headquarters.

Infectious DiseaseAntimicrobial ResistanceCystic FibrosisOncology Supportive Care

Technology Platform

CRISPR-Cas system delivered via engineered bacteriophages or probiotic bacteria to selectively target and kill antibiotic-resistant bacterial pathogens.

Funding History

2
Total raised:$60M
Series A$50M
Seed$10M

Opportunities

The global AMR crisis represents a massive, unmet medical need with strong governmental and NGO support for novel solutions.
SNIPR's first-in-class, precision approach could command premium pricing in niche prophylaxis markets (e.g., oncology) and address chronic infections in diseases like cystic fibrosis.
The platform's versatility allows for expansion into multiple bacterial targets and disease areas.

Risk Factors

The clinical and regulatory pathway for CRISPR-based antimicrobials is novel and unproven, posing significant development risk.
Scaling manufacturing for engineered phage or live biotherapeutic products is complex and costly.
Competition is emerging from other novel antimicrobial modalities, and market adoption may be slow despite clinical need.

Competitive Landscape

SNIPR operates in the emerging space of precision antimicrobials. Direct competitors include other companies developing phage therapies (e.g., Adaptive Phage Therapeutics) and those using CRISPR for antimicrobial purposes (e.g., Eligo Bioscience). It also faces indirect competition from companies developing novel small-molecule antibiotics and microbiome modulators. SNIPR's differentiation lies in its specific combination of CRISPR payloads with engineered phage/probiotic delivery.

More companies in CRISPR / Gene Editing →More companies in Denmark →